Pharmaceuticals News and Research

RSS

ARIAD announces changes in Iclusig product labeling to reflect updated safety information

ARIAD Pharmaceuticals, Inc. today announced results of its review of updated clinical data from the pivotal PACE trial of Iclusig® (ponatinib) and actions that it is taking following consultations with the U.S. Food and Drug Administration (FDA).

9 Oct 2013

Molecular Templates secures $8.5M series C financing plus $10.6M grant from CPRIT

Molecular Templates, Inc., a biopharmaceutical company focused on the discovery and development of a new class of biologic therapeutics, announced today that it recently secured an $8.5M series C financing led by Excel Venture Management. Santé Ventures, an existing investor, also participated in the round.

9 Oct 2013

New method for improving cord blood transplant success

Starting with a discovery in zebrafish in 2007, Harvard Stem Cell Institute researchers have published initial results of a Phase Ib human clinical trial of a therapeutic that has the potential to improve the success of blood stem cell transplantation.

9 Oct 2013

Binge eating disorder is different from anorexia nervosa and bulimia nervosa

Food addiction is not yet recognised as a mental disorder but certain obese individuals clearly display addictive-like behaviour towards food.

9 Oct 2013

CNIO researcher identifies new molecular mechanism that regulates genome stability, cell proliferation

Cell division is an essential process for the development of an organism. This process, however, can cause tumour growth when it stops working properly. Tumour cells accumulate alterations in their genetic material, and this makes them divide in an uncontrolled fashion, thus encouraging growth of the tumour.

9 Oct 2013

Janssen buys all rights from GSK to develop, commercialize hepatitis C compound

Janssen Pharmaceuticals, Inc. announced today the acquisition of the investigational compound GSK2336805, an NS5a replication complex inhibitor in Phase 2 development for the treatment of chronic hepatitis C, from an affiliate of GlaxoSmithKline plc.

9 Oct 2013

AquaBased introduces new eco-friendly water-based adhesive for plastic-to-plastic bonding

AquaBased Technologies, a division of ADM Tronics Unlimited, Inc. (OTCQB:ADMT), has introduced AquaTack™ 7001-PAA, a new, eco-friendly, water-based adhesive specifically designed for use in flexographic presses and other roller coater applicators for the lamination of virtually any type of low surface energy plastic films as well as for other plastic-to-plastic bonding applications.

9 Oct 2013

Evaluate launches strategic sales analytics solution that provides global view of life sciences product sales

Evaluate Ltd. today announced the launch of a strategic sales analytics solution that provides commercial teams and the investment community with a comprehensive view of life sciences product sales by country.

9 Oct 2013

NeuroVigil opens satellite research lab at NASA to develop assistive technologies for ALS

NeuroVigil, Inc. is setting to collaborate with a number of partners in the Silicon Valley where it is opening a satellite research laboratory at NASA Research Park in Mountain View, CA, to develop assistive technologies for individuals suffering from ALS and other conditions affecting the central nervous system.

9 Oct 2013

Nuventra launches innovative software platform for conducting population PK analyses

Nuventra Pharma Sciences, a specialty pharmaceutical consulting firm with global reach, is pleased to announce the launch and availability of an innovative software platform called Darwin for conducting population pharmacokinetic (PK) analyses based on a genetic algorithm paradigm.

9 Oct 2013

Healios K.K. successfully raised its target capital of 3 billion JPY (USD $30.6 million)

Healios K.K. (Headquarters: Tokyo, Japan; President and CEO: Hardy TS Kagimoto M.D.), a Japanese bioventure company at the forefront of developing innovative therapies utilizing human induced pluripotent stem cell (hiPSC) technology, is pleased to announce that it has successfully raised its target capital of 3 billion JPY (USD $30.6 million).

9 Oct 2013

Bayer HealthCare receives FDA approval for Adempas tablets

Bayer HealthCare announced today that the United States Food and Drug Administration has approved Adempas (riociguat) tablets for: (i) the treatment of adults with persistent/recurrent chronic thromboembolic pulmonary hypertension (WHO Group 4) after surgical treatment or inoperable CTEPH to improve exercise capacity and WHO functional class; and (ii) the treatment of adults with pulmonary arterial hypertension (WHO Group 1) to improve exercise capacity, improve WHO functional class and delay clinical worsening.

9 Oct 2013

Edimer doses first XLHED-affected neonate in Phase 2 trial of EDI200

Edimer Pharmaceuticals, a biotechnology company focused on developing an innovative therapy for the rare genetic disorder X-linked Hypohidrotic Ectodermal Dysplasia (XLHED), today announced the enrollment and completed dosing of the first XLHED-affected neonate in a Phase 2 trial of EDI200, the company's novel, proprietary, recombinant protein.

9 Oct 2013

Alnylam advances Development Candidate for ALN-AS1 for treatment of hepatic porphyrias

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that it is advancing its Development Candidate for ALN-AS1, an RNAi therapeutic targeting aminolevulinate synthase-1 (ALAS-1) for the treatment of hepatic porphyrias including acute intermittent porphyria (AIP).

9 Oct 2013

Arrowhead initiates Phase 1 study of ARC-520 for treatment against chronic HBV infection

Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that it completed enrollment in a Phase 1 clinical trial of ARC-520, its RNAi-based candidate against chronic hepatitis B virus infection.

9 Oct 2013

MNK-795 for acute pain management: an interview with Dr Lynn Webster

MNK-795 is a product in development that is intended to be used for acute pain. It has some unique properties. First, it is an extended release formulation, meaning that it’s going to last more than three to four hours. It was studied to be dosed once every 12 hours, and that is unique for an acute pain formulation.

8 Oct 2013

Boehringer Ingelheim’s interim data from Phase II HCV clinical collaboration with Presidio Pharmaceuticals accepted for presentation at AASLD

Boehringer Ingelheim today announced that interim data from its Phase II hepatitis C (HCV) clinical collaboration with Presidio Pharmaceuticals have been accepted for presentation as a late breaker poster at the 64th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), taking place 1-5 November in Washington, D.C. (1) The poster presentation will be on Monday 4 November.

8 Oct 2013

J&J's Janssen Buys Rights To Hepatitis C Compound From GSK

...

8 Oct 2013

LSTM professor wins Universal Biotech Innovation Prize 2013 for Hexagard

Professor Richard Pleass has won the Prix de l’Innovation 2013, also known as the Universal Biotech Innovation Prize 2013.

8 Oct 2013

Researchers re-invented class of popular antimicrobial drugs by altering their chemical structures

By tinkering with their chemical structures, researchers at the University of California, San Diego School of Medicine have essentially re-invented a class of popular antimicrobial drugs, restoring and in some cases, expanding or improving, their effectiveness against drug-resistant pathogens in animal models.

8 Oct 2013

Pharmaceuticals News and Research

ARIAD announces changes in Iclusig product labeling to reflect updated safety information

Molecular Templates secures $8.5M series C financing plus $10.6M grant from CPRIT

New method for improving cord blood transplant success

Binge eating disorder is different from anorexia nervosa and bulimia nervosa

CNIO researcher identifies new molecular mechanism that regulates genome stability, cell proliferation

Janssen buys all rights from GSK to develop, commercialize hepatitis C compound

AquaBased introduces new eco-friendly water-based adhesive for plastic-to-plastic bonding

Evaluate launches strategic sales analytics solution that provides global view of life sciences product sales

NeuroVigil opens satellite research lab at NASA to develop assistive technologies for ALS

Nuventra launches innovative software platform for conducting population PK analyses

Healios K.K. successfully raised its target capital of 3 billion JPY (USD $30.6 million)

Bayer HealthCare receives FDA approval for Adempas tablets

Edimer doses first XLHED-affected neonate in Phase 2 trial of EDI200

Alnylam advances Development Candidate for ALN-AS1 for treatment of hepatic porphyrias

Arrowhead initiates Phase 1 study of ARC-520 for treatment against chronic HBV infection

MNK-795 for acute pain management: an interview with Dr Lynn Webster

Boehringer Ingelheim’s interim data from Phase II HCV clinical collaboration with Presidio Pharmaceuticals accepted for presentation at AASLD

J&J's Janssen Buys Rights To Hepatitis C Compound From GSK

LSTM professor wins Universal Biotech Innovation Prize 2013 for Hexagard

Researchers re-invented class of popular antimicrobial drugs by altering their chemical structures

Event guide: World ADC San Diego eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence